GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » TrivarX Ltd (OTCPK:MDBIF) » Definitions » Capex-to-Revenue

MDBIF (TrivarX) Capex-to-Revenue : 0.00 (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is TrivarX Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

TrivarX's Capital Expenditure for the six months ended in Dec. 2023 was $-0.91 Mil. Its Revenue for the six months ended in Dec. 2023 was $0.00 Mil.

GuruFocus do not calculate Capex-to-Revenue if the revenue is negative.


TrivarX Capex-to-Revenue Historical Data

The historical data trend for TrivarX's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TrivarX Capex-to-Revenue Chart

TrivarX Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.55 17.96 74.54 101.07 -

TrivarX Semi-Annual Data
Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 40.42 42.73 - - -

Competitive Comparison of TrivarX's Capex-to-Revenue

For the Health Information Services subindustry, TrivarX's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TrivarX's Capex-to-Revenue Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, TrivarX's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where TrivarX's Capex-to-Revenue falls into.



TrivarX Capex-to-Revenue Calculation

TrivarX's Capex-to-Revenue for the fiscal year that ended in Jun. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-1.516) / 0.015
=101.07

TrivarX's Capex-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (-0.905) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TrivarX  (OTCPK:MDBIF) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


TrivarX Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of TrivarX's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


TrivarX Business Description

Traded in Other Exchanges
Address
647 Beaufort Street, Mount Lawley, WA, AUS, 6050
TrivarX Ltd is a health technology company developing AI-driven, scientifically-based devices for screening and diagnosis of behavioral health conditions. Trivarx's clinical research has enabled the development of cutting-edge proprietary algorithms for spectral analyses of sleep architecture and heart rate variability.

TrivarX Headlines

From GuruFocus

Medibio Granted CE Mark Approval for MEBsleep

By PRNewswire PRNewswire 01-19-2021

Medibio Named Finalist for Prestigious Optus My Business Award

By Marketwired Marketwired 10-01-2018

Medibio Market Update

By Marketwired Marketwired 11-02-2018

Medibio Announces Scientific Advisory Board

By Marketwired Marketwired 04-26-2018

Peer-reviewed Neurology Publication on Medibio Science

By Marketwired Marketwired 06-27-2018